How is CIDP different from Guillain-Barré syndrome?

Both are immune attacks on peripheral nerve myelin, but Guillain-Barré develops rapidly over days to four weeks and is usually a single episode, often after an infection. CIDP progresses more slowly over at least eight weeks and follows a chronic or relapsing course that needs ongoing treatment. The treatments overlap, but corticosteroids help CIDP and not Guillain-Barré.

Will I need treatment for life?

Not necessarily. Some people achieve remission and can gradually stop treatment under supervision, while others need long-term maintenance therapy to prevent relapse. Your neurologist will periodically test whether treatment can be reduced. Never stop immune therapy on your own, as relapses can cause lasting nerve damage.

Can the nerve damage be reversed?

Myelin can regenerate, so weakness and numbness often improve substantially once inflammation is controlled, especially when treatment starts early. If the nerve fibers themselves (axons) have been damaged by prolonged inflammation, recovery is slower and may be incomplete, which is why timely diagnosis matters.

NeurologicalICD-10: G61.81Rare; the most common treatable chronic autoimmune neuropathy, more frequent in older men

Chronic Inflammatory Demyelinating Polyneuropathy

Also known as: CIDP, Chronic relapsing polyneuropathy

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune disorder in which the immune system attacks the myelin sheath that insulates peripheral nerves, slowing or blocking the signals between the brain and the body. It causes progressive weakness and numbness, typically on both sides of the body and in both the arms and legs, developing over at least eight weeks. CIDP is considered the chronic counterpart of Guillain-Barré syndrome and may follow a steadily progressive or relapsing course. Untreated, it can lead to significant disability, but it is one of the more treatable neuropathies: immune therapies such as intravenous immunoglobulin, corticosteroids, and plasma exchange help most people regain strength.

At a Glance

Common symptoms: Progressive, symmetrical weakness in the legs and arms, affecting both close-to-body and distal muscles, Tingling, numbness, or loss of sensation in the hands and feet, Difficulty walking, climbing stairs, or rising from a chair
Main treatments: Intravenous immunoglobulin (IVIG) or subcutaneous immunoglobulin as first-line therapy, Corticosteroids, either oral or in pulsed intravenous doses, Plasma exchange to remove harmful antibodies, especially for severe or rapidly worsening disease
Category: Neurological · Rare; the most common treatable chronic autoimmune neuropathy, more frequent in older men
See a doctor if: Weakness or numbness in the arms and legs that is progressing over weeks

Symptoms

Progressive, symmetrical weakness in the legs and arms, affecting both close-to-body and distal muscles

Tingling, numbness, or loss of sensation in the hands and feet

Difficulty walking, climbing stairs, or rising from a chair

Loss of balance and reduced or absent reflexes

Fatigue

Clumsiness with fine tasks such as buttons or writing

Less commonly, pain, tremor, or difficulty swallowing

Causes

An autoimmune attack on peripheral nerve myelin; the exact trigger is unknown
Antibody- and cell-mediated inflammation of the nerve roots and nerves
In a small subgroup, specific antibodies against proteins at the nodes of Ranvier
Possible association with preceding infections in some cases

Risk Factors

Being male and older adult, though CIDP can occur at any age
Diabetes, which is more common in people with CIDP
Other autoimmune conditions
Certain blood disorders such as monoclonal gammopathy
HIV infection in rare cases

Diagnosis

Neurological examination showing symmetrical weakness, sensory loss, and reduced reflexes progressing over two months or more
Nerve conduction studies and electromyography showing demyelination
Lumbar puncture, which typically shows raised protein with normal cell counts
Blood tests to exclude diabetes, vitamin deficiencies, paraproteins, and other causes of neuropathy
MRI of the nerve roots or nerve ultrasound, and occasionally nerve biopsy, in uncertain cases

Treatment

Intravenous immunoglobulin (IVIG) or subcutaneous immunoglobulin as first-line therapy
Corticosteroids, either oral or in pulsed intravenous doses
Plasma exchange to remove harmful antibodies, especially for severe or rapidly worsening disease
Immunosuppressant medications or newer targeted therapies for people who do not respond to standard treatment
Physiotherapy and occupational therapy to maintain strength, balance, and independence
Supportive: regular, moderate exercise within tolerance to prevent deconditioning
Supportive: fall prevention at home, orthotics or walking aids when needed, and attention to foot care given reduced sensation

Prevention

There is no known way to prevent CIDP
Seek prompt assessment of progressive weakness or numbness, since early treatment limits nerve damage
Adhere to maintenance treatment schedules to prevent relapses
Keep diabetes and other health conditions well controlled
Stay physically active to preserve muscle strength

When to See a Doctor

Weakness or numbness in the arms and legs that is progressing over weeks
Increasing difficulty walking, climbing stairs, or using your hands
Falls or loss of balance
Rapidly worsening weakness or trouble breathing or swallowing (seek urgent care)
Return of symptoms after a period of improvement, which may signal relapse

Frequently Asked Questions

Related Conditions

Guillain-Barré Syndrome

Neurological

Peripheral Neuropathy

Neurological

Diabetic Neuropathy

Neurological

Multiple Sclerosis

Autoimmune

Myasthenia Gravis

Autoimmune

Have questions about Chronic Inflammatory Demyelinating Polyneuropathy?

Ask Mother Nature AI for personalized, evidence-based guidance.

Ask about Chronic Inflammatory Demyelinating Polyneuropathy

Medical Disclaimer: This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

Content reviewed against peer-reviewed medical literature and clinical guidelines. Read our editorial standards.